Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson’s disease and Atypical Parkinsonian syndromes using DaTSCAN® SPECT
暂无分享,去创建一个
Göran Granerus | Nil Dizdar | Anette Davidsson | H. Zachrisson | Charalampos Georgiopoulos | N. Dizdar | Helene Zachrisson | G. Granerus | Charalampos Georgiopoulos | Anette Davidsson
[1] S. Gilman,et al. Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.
[2] A. Antonini,et al. EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease , 2013, European journal of neurology.
[3] L. Timmermann,et al. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease , 2012, Journal of Neurology.
[4] S. Asenbaum,et al. SPECT and PET imaging of the dopaminergic system in Parkinson's disease , 2000, Journal of Neurology.
[5] W. Meissner,et al. Multiple system atrophy: current and future approaches to management , 2010, Therapeutic advances in neurological disorders.
[6] M. McKeown,et al. Invited Article: Functional imaging in Parkinson disease , 2008, Neurology.
[7] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[8] Robert B. Innis,et al. [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .
[9] Jan Booij,et al. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. , 2007, Parkinsonism & related disorders.
[10] John Seibyl,et al. SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.
[11] Xanthi Pedeli,et al. Interobserver variability, and visual and quantitative parameters of 123I-FP-CIT SPECT (DaTSCAN) studies , 2012, Annals of Nuclear Medicine.
[12] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[13] I. McKeith,et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.
[14] K. Jellinger. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.
[15] Dae Hyuk Moon,et al. Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.
[16] Koen Van Laere,et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[17] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[18] B. Långström,et al. Regulation of dopaminergic activity in early Parkinson's disease , 1999, Annals of neurology.
[19] A. Jon Stoessl,et al. Neuroimaging in Parkinson’s Disease , 2011, Neurotherapeutics.
[20] L. Wojtecki,et al. Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach , 2011, The Journal of Nuclear Medicine.
[21] F. Zhang,et al. Resveratrol Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity through Its Anti-Inflammatory Actions , 2010, Molecular Pharmacology.
[22] J. Seibyl,et al. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. , 2001, Movement disorders : official journal of the Movement Disorder Society.
[23] H. Berendse,et al. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. , 2009, Parkinsonism & related disorders.
[24] R. Nagele,et al. Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera , 2011, PloS one.
[25] W. Poewe,et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial , 2013, The Lancet Neurology.
[26] M. Savoiardo. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging , 2003, Neurological Sciences.
[27] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[28] Donald Grosset,et al. Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.
[29] R J Jaszczak,et al. Whole-body single-photon emission computed tomography using dual, large-field-of-view scintillation cameras , 1979, Physics in medicine and biology.
[30] Andrew J Lees,et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.
[31] K. Riklund,et al. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[32] Masanori Ichise,et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP , 2002, Movement disorders : official journal of the Movement Disorder Society.
[33] C. Blomstrand,et al. Functional assessment of high-grade ICA stenosis with duplex ultrasound and transcranial Doppler , 2012, Clinical physiology and functional imaging.